Amplia Therapeutics and Australia New Zealand Gynaecological Oncology Group (Anzgog) Announce Ovarian Cancer Study
May 08, 2026 20:45 ET | Source: Amplia Therapuetics Limited Melbourne, Australia,…
Orchard Therapeutics Awarded Innovation Passport Designation for OTL-201 in MPS-IIIA
LONDON, April 30, 2026 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a Kyowa Kirin…
Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-A Trial on April 27, 2026
April 26, 2026 12:00 ET | Source: Oruka Therapeutics, Inc. MENLO PARK,…
Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy
AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.…
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 24, 2026 08:00 ET | Source: Aligos Therapeutics SOUTH SAN FRANCISCO,…
Vivos Therapeutics Reports Full Year 2025 Financial Results
April 15, 2026 16:20 ET | Source: Vivos Therapeutics, Inc Full Year…
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates on April 23, 2026
Vivoryon Therapeutics N.V. to Report Full Year 2025 Financial Results and Business Updates…
Asgard Therapeutics appoints Professor Dr Wolfram Brugger as Chief Medical Officer as it advances transformative personalized off-the-shelf immunotherapy toward clinical development
April 14, 2026 03:30 ET | Source: Asgard Therapeutics Medical oncologist (ex…
AnBogen Therapeutics to Present Dual Breakthroughs for Imofinostat (ABT-301) at AACR 2026: Addressing Immunotherapy Barriers in CRC and Chemo-resistance in Pancreatic Cancer
TAIPEI, April 13, 2026 /PRNewswire/ -- AnBogen Therapeutics, a clinical-stage biotechnology company…
Pelthos Therapeutics Announces CFO Transition
Senior Vice President, Finance & Accounting John M. Gay named Chief Financial…
